StreetAlpha.app
Home › Stocks › AVBP

ArriVent BioPharma, Inc. (AVBP)

Healthcare
$10.52
▼ −6.57%
LAST CLOSE · NOV 20

ArriVent BioPharma develops cancer medicines, led by firmonertinib for certain types of lung cancer. It last closed at $10.52 on Nov 20, down 6.57% on the day. The next earnings report for AVBP is expected around Thu, Mar 4, 2027, after the close. For the quarter ended Sep 2026, AVBP reported EPS of -$0.81 on revenue of $5.0M. Over its last 8 reports the stock moved an average of 3.8% the session after earnings. Over the last 12 months AVBP insiders bought $0 of stock on the open market and sold $13.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is AVBP in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AVBP.

Key Stats

Last 12 months
Results
Net income
−$169.1M
EPS (diluted)
−$3.60
Valuation
Market cap
$544.1M
51.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$113.6M
At Sep 30
Shareholder equity
$393.5M
Shares outstanding
51.7M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: −$69.3M−$69.3MFY2023FY2024: −$80.5M−$80.5MFY2024FY2025: −$166.3M−$166.3MFY2025

From AVBP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 4
Estimated date · After the close
Reported EPS
-$0.81
Quarter ended Sep 2026
Year ago EPS
-$0.83
Same quarter last year
Revenue
$5.0M
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.61Dec '24Mar 2025: -$1.90Mar '25Jun 2025: -$0.90Jun '25Sep 2025: -$0.83Sep '25Dec 2025: -$0.78Dec '25Mar 2026: -$0.96Mar '26Jun 2026: -$1.05Jun '26Sep 2026: -$0.81Sep '26Latest -$0.81
Revenue by quarter
Not enough quarters on file yet.
How AVBP moved after its last 8 reports
Average move the session after a report ±3.8%
Nov 9, 2026After the close−4.7%
Aug 12, 2026After the close−4.6%
May 11, 2026After the close−0.2%
Mar 5, 2026After the close−7.2%
Nov 10, 2025Time not announced+3.1%
Aug 11, 2025Time not announced−3.3%
May 12, 2025Time not announced−0.8%
Mar 3, 2025Time not announced−6.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on AVBPStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on AVBP
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on AVBP

Technical Analysis

AVBP · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 26% below its 20 day and 85% below its 50 day average. It is 149% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $10.33, and the nearest resistance the Pivot at $10.75.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 13.0%/day
Key levels
$35.8352 week high+240.6%
$26.20200 day average+149.0%
$25.21100 day average+139.6%
$19.4850 day average+85.2%
$15.05Swing high (Nov 10)+43.1%
$13.2620 day average+26.0%
$11.12Pivot R1+5.7%
$10.75Pivot+2.2%
$10.52Last close
$10.3352 week low−1.8%
$10.15Pivot S1−3.5%
Indicators
RSI (14)29.44Oversold below 30Oversold
MACD-2.32Above its signal lineBullish
Stochastic11.2Near the bottom of its rangeOversold
ADX (14)34.1Trending down
Williams %R-96.0Oversold below −80, overbought above −20Oversold
CCI (20)-135.0Oversold below −100, overbought above 100Oversold
Rate of change−22.9%Change over 10 sessionsBearish
ATR (14)$1.37Typical daily range, 13.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AVBP

What happened before

See how AVBP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for AVBPHow many large options trades hit AVBP, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

AVBP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲85 buying vs 61 selling
  • ▲Held by funds +8.4 pts
  • ▼Funds holding -5
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding153158−3.2%
In funds' top 1011110.0%
Held by funds97.6%89.2%+8.4 pts
New / increased15 / 7034 / 70−18.3%
Reduced / sold out41 / 2030 / 15+35.6%
Put/call ratio1.270.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AVBP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AVBP Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$13.0M1 sale · 1 insider
2025-12 sold $13.0MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Dec 10, 2025Hhlr Advisors, Ltd.10% ownerSale555,555$23.37$13.0M
Every insider buy and sale for AVBP over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See AVBP insider trades →

From SEC Form 4 filings by AVBP's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AVBP is in one of them and how their past AVBP trades turned out.

AVBP in the AI portfolios
Loading…

AVBP News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AVBP in an article yet. Here's the latest on the wider market.

AVBP in the news

About ArriVent BioPharma

ArriVent BioPharma is a clinical stage biopharmaceutical company based in Newtown Square, Pennsylvania. It develops cancer treatments for patients, with its lead candidate, firmonertinib, aimed at non-small cell lung cancer linked to certain EGFR gene mutations. The company is also developing antibody drug conjugates, including ARR 217, for solid tumors. Its candidates are still in clinical trials and have not been approved by the U.S. Food and Drug Administration.

Headquarters
Newtown Square, PA